Physician profile
Lucas E Redd
NPI 1932341435
$106.10
in general payments reported to CMS, 2019-2025
5 companies · $29.93 in 2025
The $29.93 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.83 · 2023: $48.34 · 2025: $29.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.93 | 2025 | |
| Shionogi INC | $25.42 | 2023 | Fetroja |
| Roche Diagnostics Corporation | $22.92 | 2023 | Pathway Anti-Her-2/Neu (4b5) Rabbit Monoclonal Primary Antibody |
| Abbott Laboratories | $16.01 | 2022 | |
| Merck Sharp & Dohme LLC | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Redd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.